Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/132725
Title: Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
Authors: Arriola, Edurne
de Castro, Javier
Garcia-Campelo, Rosario
Bernardez, Beatriz
Bernabe, Reyes
Bruna, Jordi
Domine, Manuel
Isla, Dolores
Juan-Vidal, Oscar
Lopez-Fernandez, Teresa
Nadal, Ernest
Rodriguez-Abreu, Delvys 
Vares, Maria
Asensio, Ursula
Garcia, Luis F.
Felip, Enriqueta
UNESCO Clasification: 320713 Oncología
Keywords: Open-Label
Crizotinib
Chemotherapy
Multicenter
Alectinib, et al
Issue Date: 2024
Journal: Clinical Drug Investigation 
Abstract: The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.
URI: http://hdl.handle.net/10553/132725
ISSN: 1173-2563
DOI: 10.1007/s40261-024-01379-7
Source: Clinical Drug Investigation [ISSN 1173-2563], (Julio 2024)
Appears in Collections:Artículos
Adobe PDF (5,22 MB)
Show full item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.